aiwiki.page
English
Science / Biology / insulin-receptor

Insulin Receptor

The insulin receptor is a cell-surface enzyme-linked receptor that mediates insulin’s effects on glucose metabolism, nutrient storage, growth, and other cellular processes.

27 keywords2 linked from4 not yet writtenWritten by AI
Cell MembraneProteinInsulinGeneDisulfide BondEndoplasmic Reti…GlycosylationAlternative Spli…Insulin Re…

The insulin receptor is a cell-membrane protein that binds insulin and initiates signals regulating nutrient use, storage, and cellular growth. Encoded by the human INSR gene, it belongs to the receptor tyrosine kinase family: receptors whose intracellular regions act as enzymes that transfer phosphate groups to tyrosine residues in proteins. Its best-established physiological functions include promoting glucose uptake in skeletal muscle and adipose tissue and helping suppress glucose production by the liver. Defects in the receptor can cause rare, severe disorders of insulin action, although most common insulin resistance involves a broader network of cellular and physiological changes.

Molecular structure and synthesis

The mature insulin receptor consists of two extracellular α subunits and two membrane-spanning β subunits, held together by disulfide bonds. It is commonly described as an α2β2\alpha_2\beta_2 heterotetramer. It can also be understood as a covalently linked dimer of two processed αβ receptor units.

Each αβ unit is initially synthesized as a single precursor chain. During processing in the endoplasmic reticulum and Golgi apparatus, the precursor undergoes glycosylation, folding, and proteolytic cleavage. The resulting subunits remain associated through disulfide bonds.

The α subunits lie outside the cell and contribute extensively to insulin binding. Each β subunit contains an extracellular segment, a single membrane-spanning helix, and an intracellular portion comprising a juxtamembrane region, a tyrosine kinase domain, and a carboxyl-terminal tail.

The extracellular region contains leucine-rich, cysteine-rich, and fibronectin type III domains. Insulin-binding surfaces are assembled from elements contributed by both halves of the receptor. Consequently, ligand recognition is not simply an interaction between insulin and an isolated α subunit.

Unlike many receptor tyrosine kinases, which become activated through ligand-induced association of separate receptor molecules, the insulin receptor is already a disulfide-linked dimer before insulin binds. Activation principally requires rearrangement of this preassembled structure.

Receptor isoforms and related receptors

Alternative splicing of INSR produces two major isoforms:

  • IR-A lacks the 12-amino-acid segment encoded by exon 11.
  • IR-B includes this segment near the carboxyl terminus of the α subunit.

Both isoforms bind insulin and transmit signals. IR-B is prominent in several differentiated tissues with major metabolic functions, including liver. IR-A is relatively abundant in fetal tissues and occurs in various adult tissues and tumors. These distributions overlap rather than defining mutually exclusive tissue categories.

IR-A also binds insulin-like growth factor II more effectively than IR-B does. This difference contributes to variation in receptor responses, but the isoforms cannot be classified simply as “growth” and “metabolic” receptors: their effects also depend on ligand availability, receptor abundance, and the signaling machinery of the cell.

The insulin receptor is closely related to the insulin-like growth factor 1 receptor (IGF1R). Cells expressing both can assemble hybrid receptors containing one insulin-receptor αβ unit and one IGF1R αβ unit. Their ligand-binding properties differ from those of receptors composed entirely of insulin-receptor subunits.

Ligand binding and activation

Insulin acts as the receptor’s principal physiological ligand. Binding changes the relative arrangement of the extracellular domains and membrane-spanning regions, enabling the intracellular kinase domains to activate one another.

The kinase domains use adenosine triphosphate (ATP) as a phosphate donor. During trans-autophosphorylation, one receptor kinase domain phosphorylates tyrosine residues on the other. Phosphorylation of the activation loop increases catalytic activity, while additional phosphorylated sites help recruit intracellular signaling proteins.

A simplified representation of the kinase reaction is:

ATP+protein–tyrosine⟶ADP+protein–phosphotyrosine.\text{ATP}+\text{protein–tyrosine} \longrightarrow \text{ADP}+\text{protein–phosphotyrosine}.

The receptor therefore functions both as an enzyme and as a signaling platform. Activation does not itself transport glucose across the membrane; it changes the activity and localization of downstream proteins that control transport and metabolism.

Insulin binding can exhibit negative cooperativity, meaning that occupancy of one binding site can alter the affinity or dissociation behavior of insulin at another. The receptor’s behavior is therefore more complex than a set of independent, identical binding sites. Structural studies also show that receptor conformation and ligand occupancy vary with experimental conditions.

Intracellular signaling

Activated receptors phosphorylate adaptor proteins, notably members of the insulin receptor substrate family, including IRS-1 and IRS-2. These proteins provide docking sites for signaling enzymes. Two extensively studied downstream branches are the PI3K–AKT pathway and the RAS–MAPK pathway.

PI3K–AKT signaling

Phosphorylated IRS proteins recruit phosphoinositide 3-kinase, or PI3K. PI3K generates phosphoinositide signals at the inner surface of the membrane, helping recruit and activate AKT and associated regulators.

This pathway coordinates several major metabolic responses:

  • Glucose uptake: In skeletal muscle and adipose tissue, signaling promotes movement of vesicles containing GLUT4 to the cell surface, increasing the capacity for glucose uptake.
  • Glycogen storage: Signaling favors glycogen synthesis through regulation of glycogen synthase and associated enzymes.
  • Hepatic glucose production: Insulin-dependent regulation of transcription factors, together with other mechanisms, contributes to suppression of gluconeogenesis.
  • Lipid metabolism: Insulin promotes lipid storage and suppresses the breakdown of stored fat in adipose tissue.
  • Protein synthesis and growth: AKT-linked pathways influence protein synthesis and cellular growth through regulators including mTOR.

These effects are tissue-specific. Liver cells, for example, do not use GLUT4 as their principal glucose transporter; insulin regulates hepatic metabolism mainly through effects on enzymes, substrate handling, and gene expression.

RAS–MAPK signaling

Through adaptor proteins such as SHC and GRB2, receptor activation can engage RAS and the RAF–MEK–ERK kinase cascade. This branch influences gene expression, differentiation, and cell proliferation.

The division between “metabolic” PI3K–AKT signaling and “growth-related” MAPK signaling is useful but incomplete. The pathways interact, share regulatory mechanisms, and produce different outcomes depending on cell type and physiological context.

Regulation and receptor trafficking

Insulin signaling is regulated at several levels. Protein tyrosine phosphatases remove phosphate groups from the receptor or its substrates, opposing kinase activity. Other regulatory proteins modify IRS abundance, localization, or phosphorylation state.

After activation, receptors can be internalized into endosomes. Some return to the cell surface, while others are directed toward degradation in the lysosome. Internalization is not equivalent to immediate signal termination: signaling can continue from intracellular compartments.

Receptor recycling and degradation influence the number of receptors available at the surface. Downstream pathways also generate feedback that adjusts signaling strength and duration. Consequently, a cell’s response to insulin depends not only on insulin concentration, but also on receptor abundance, trafficking, substrate availability, and the state of intracellular regulatory networks.

Physiological and clinical significance

Insulin resistance

Insulin resistance is a reduced biological response to insulin. It can arise from changes in receptor abundance or function, but also from defects or alterations downstream of the receptor. Lipid-associated signaling changes, inflammation, and tissue-level interactions can contribute.

Common insulin resistance should therefore not be equated with an INSR mutation or a complete failure of receptor binding. Different insulin-regulated processes may also become impaired to different degrees.

Inherited receptor disorders

Rare pathogenic variants in INSR can impair receptor synthesis, processing, transport to the cell surface, insulin binding, or kinase activity.

Biallelic variants can cause Donohue syndrome or Rabson–Mendenhall syndrome, disorders associated with severe insulin resistance and abnormalities of growth and metabolism. Some heterozygous variants cause forms of type A insulin resistance. The clinical effects depend on the particular variant and its impact on receptor function; these disorders cannot be distinguished by receptor abundance alone.

Autoantibodies

Rarely, an autoantibody response against the insulin receptor causes type B insulin resistance. Receptor-directed antibodies can interfere with insulin action, but some can also stimulate receptor activity. This helps explain why affected individuals may experience severe hyperglycemia, hypoglycemia, or both at different times.

Growth signaling and cancer research

Because the insulin receptor participates in growth-related signaling and overlaps functionally with the IGF system, it is studied in cancer biology. However, receptor expression or activation alone does not establish that it drives a particular tumor. Interpretation requires attention to receptor isoforms, hybrid receptors, ligand supply, and the wider signaling network.

Discovery and research methods

Biochemical studies in the 1970s established specific insulin binding at cell surfaces. Work in the early 1980s identified insulin-stimulated tyrosine phosphorylation associated with the receptor. Cloning of the human receptor complementary DNA in 1985 revealed its precursor organization and relationship to other tyrosine kinases.

X-ray crystallography subsequently clarified the organization of receptor domains and the kinase activation mechanism. More recent cryo-electron microscopy studies have visualized large receptor complexes in different ligand-bound states, revealing how insulin binding can be coupled to extensive structural rearrangement.

Research methods include ligand-binding assays, measurements of receptor phosphorylation, cell-based signaling assays, and genetic manipulation of receptor expression. Each measures a different aspect of receptor behavior: ligand affinity, kinase activation, downstream signaling, and whole-cell metabolic response are related but not interchangeable. Results from purified receptor fragments or engineered cells must therefore be interpreted in light of the more complex environment of intact tissues.